FDA Reminds Doctors, Patients To Enroll in Avandia Access Program

The Food and Drug Administration Nov. 4 reminded health care providers and patients that they need to enroll in the access program for rosiglitazone by Nov. 17 to continue prescribing and receiving rosiglitazone-containing medicines.

Those medicines include Avandia (rosiglitazone), Avandamet (rosiglitazone and metformin), and Avandaryl (rosiglitazone and glimepiride), the agency said. The three drugs are manufactured by GlaxoSmithKline.

In May, FDA announced it is imposing new restrictions on these three rosiglitazone-containing drugs that are used to treat type 2 diabetes (9 PLIR 645, 5/27/11).

Availability.

After Nov. 18, rosiglitazone medicines will not be available through retail pharmacies and ...